Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Single most important change

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Aug 30, 2022 2:15am

289 Views

Post# 34928755

RE:RE:Single most important change

CancerSlayer wrote:
As reported in the 5/30/2022 MD&A for 360 day data:

5 of 23 evaluable patients were CR (22%)...2 patients from Ph1b
4 of 23 evaluable patients were PR (17%)

Today's report:

9 of 26 evaluable patients were CR (35%)...2 patients from Ph1b
3 of 26 evaluable patients were PR (12%)

As of today, there are 4 additional 360 day CR patients & an increase in 3 total evaluable patients (23 to 26) since 5/30. All 4 additional CR patients received two optimized treatments & 1 of the 4 appears to have converted from PR to CR. The one who converted may either have converted naturally post the 2nd treatment or was found to have UTUC or cancer outside of the bladder (a de facto CR). The moral of this story...full optimization works & not all PRs are bad ; ).

Upon further review of the May 30 data reported...

360 day 450 day

CR 5 5

PR 4 2

NR 14 15

P 18 19

It appears one of the 360 day PRs converted to an NR & the other one was still pending at 450 days. This suggests the one pending PR patient at 450 days was ultimately found to have UTUC & was therefore converted to a CR for the 360 day assessment. So this PR patient would not have naturally converted to CR as I mistakenly noted in my prior post...